Search

Lapretolimod

Lapretolimod is under investigation in clinical trial NCT03799510 (Anti-Schistosomiasis Vaccine: Sm14 Phase 2b-Sn in School Children). Lapretolimod has a monoisotopic molecular weight of 1745.28 Da. … The usage of the INN stem '-tolimod' in the name indicates that Lapretolimod is a toll-like receptor (TLR) agonist.

Sodium chlorite

Used as an agent for cleaning drinking water. It is also used as an additive in products like toothpaste and mouthwash. Acidified sodium chlorite was approved by the U.S. … Food and Drug Administration as of 2004, as an anti-microbial agent which is non-toxic, but not as a drug [A174811, L5413].

Rolicyclidine

Because of its pharmacodynamic similarity to the drug phencyclidine (PCP), rolicyclidine was added to the Schedule I list of illegal drugs in the USA in the 1970s.

Zastaprazan

The usage of the INN stem '-prazan' in the name indicates that Zastaprazan is a proton pump inhibitor, not dependent on acid activation. … Zastaprazan is under investigation in clinical trial NCT05814809 (Clinical Trial to Evaluate the Safety and Pharmacokinetics of JP-1366 in Healthy Adult Volunteers).

Deanol

It has been also used as an ingredient in skin care, and in cognitive function- and mood-enhancing products. … Deanol has been used in the treatment of attention deficit-hyperactivity disorder (ADHD), Alzheimer's disease, autism, and tardive dyskinesia.

N,N,N-trimethylglycinium

Betaine has also been used in the treatment of liver disorders, for hyperkalemia, for homocystinuria, and for gastrointestinal disturbances. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1341) … A naturally occurring compound that has been of interest for its role in osmoregulation.

Linaprazan

The usage of the INN stem '-prazan' in the name indicates that Linaprazan is a proton pump inhibitor, not dependent on acid activation. … Linaprazan is under investigation in clinical trial NCT00206284 (A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients Without Erosive Esophagitis.).

AP5280

AP5280 is a novel N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound platinum (Pt) therapeutic designed to increase the therapeutic index relative to conventional, small-molecule platinum agents.

Vercirnon

It is under investigation in clinical trial NCT01611805 (Japanese Phase I of GSK1605786). … Vercirnon is a novel, orally active anti-inflammatory agent that targets a chemokine receptor protein implicated in both Crohn's disease and ulcerative colitis, the two principal forms of IBD.

AZX-100